Does infliximab-dyyb (infliximab) cause hypertension in a 15‑year‑old adolescent?

Infliximab-dyyb Does Not Typically Cause Hypertension in 15-Year-Olds

Infliximab-dyyb is not recognized as a common cause of hypertension in adolescents, though rare case reports exist. The FDA drug label for infliximab-dyyb does not list hypertension as a known adverse effect 1. If hypertension develops in a 15-year-old on infliximab-dyyb, you should first investigate other causes before attributing it to the medication.

Understanding the Evidence

What the Drug Label Says

The FDA-approved labeling for infliximab-dyyb extensively details serious adverse effects including infections, malignancies (particularly lymphomas in adolescents), and infusion reactions 1. Notably absent from this comprehensive safety profile is any mention of hypertension as a recognized adverse effect. This is significant because the drug has been studied in pediatric populations, including adolescents, and cardiovascular effects would have been documented if they were clinically meaningful.

The Rare Case Report

One isolated case report from 2022 described a 38-year-old adult with Crohn's disease who developed hypertension temporally associated with infliximab infusions 2. However, this represents:

• A single case in an adult, not an adolescent
• Blood pressure that rose acutely during infusions and normalized after discontinuation
• No established causal mechanism
• No supporting evidence from clinical trials or other case reports

Contradictory Evidence: Infliximab May Lower Blood Pressure

Interestingly, a 2014 study in rheumatoid arthritis patients found that infliximab reduced 24-hour ambulatory blood pressure, particularly morning and daytime readings 3. This effect was associated with decreased sympathetic nervous system activity. While this study was in adults with RA (not adolescents with IBD), it suggests that if anything, infliximab's anti-inflammatory effects might lower rather than raise blood pressure.

Clinical Approach for a 15-Year-Old

Primary Hypertension Risk Factors in Adolescents

In a 15-year-old, 85-95% of hypertension is primary (not secondary) 4. The strongest risk factors are 4:

• Elevated body mass index (most important)
• Male sex
• Family history of hypertension
• Ethnicity (higher in Hispanic and African American adolescents)

Proper Blood Pressure Assessment

Before concluding hypertension exists 5, 6:

1. Measure BP using auscultation (not automated devices) after 5 minutes of rest, seated, right arm at heart level
2. Use age-, sex-, and height-adjusted percentiles for interpretation
3. Confirm elevated readings at 3 separate visits unless symptomatic
4. For adolescents ≥13 years: hypertension is defined as BP ≥130/80 mmHg or ≥95th percentile
5. Consider ambulatory blood pressure monitoring to rule out white coat hypertension (false-positive rates are a concern in adolescents) 4

Investigation Algorithm

If confirmed hypertension in a 15-year-old on infliximab-dyyb:

Step 1: Assess for obesity and metabolic syndrome (the most likely cause)

Step 2: Review medication timing

• Does BP elevation occur only during/immediately after infusions? (suggests rare infusion-related phenomenon like the single case report)
• Is BP persistently elevated between infusions? (suggests unrelated primary or secondary hypertension)

Step 3: Screen for secondary causes if:

• BP is stage 2 (>99th percentile + 5 mmHg or >140/90 mmHg)
• Patient is not overweight/obese
• No family history of hypertension
• Look for: renal disease, renovascular disease, endocrine disorders 4

Step 4: Consider other medications or substances

• Corticosteroids (commonly used with infliximab in IBD)
• NSAIDs
• Oral contraceptives
• Stimulants

Management Recommendations

Do not discontinue infliximab-dyyb based solely on hypertension unless:

• BP rises acutely and reproducibly during infusions (mimicking the single case report pattern)
• All other causes have been excluded
• The temporal relationship is clear and consistent

Instead:

1. Initiate lifestyle modifications first 4: weight reduction if overweight, increased physical activity (30-60 minutes, 3-5 days/week), DASH diet, sodium restriction
2. Consider adding antihypertensive medication if stage 2 hypertension or stage 1 unresponsive to lifestyle changes 4
3. Continue monitoring for infliximab's known serious adverse effects in adolescents: infections (especially tuberculosis), lymphomas, and hepatosplenic T-cell lymphoma 1

Important Caveats

• The evidence linking infliximab to hypertension consists of one case report in an adult 2
• Adolescents with inflammatory bowel disease often receive concomitant corticosteroids, which are a well-established cause of hypertension
• The prevalence of obesity-related hypertension in adolescents is increasing 4, making it statistically far more likely than a drug effect
• Infliximab's known serious risks in adolescents (malignancies, infections) far outweigh the theoretical risk of hypertension 1

The clinical decision should prioritize maintaining disease control with infliximab while appropriately investigating and managing hypertension through standard approaches for adolescents.